UBS Maintains Buy on AdaptHealth, Lowers Price Target to $14

ADAPTHEALTH CORP

ADAPTHEALTH CORP

AHCO

0.00

UBS analyst Kevin Caliendo maintains AdaptHealth (NASDAQ: AHCO) with a Buy and lowers the price target from $15 to $14.